Related references
Note: Only part of the references are listed.Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis
Bernard Bannwarth et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2012)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis
Cheng-Tao Yang et al.
CLINICAL RHEUMATOLOGY (2012)
Tofacitinib for the treatment of rheumatoid arthritis
Cristiano A. F. Zerbini et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
Kalle J. Aaltonen et al.
PLOS ONE (2012)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
J. H. Coombs et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
Richard J. Riese et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2010)
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment
Stanley Cohen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2009)
A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis
Astrid Wiens et al.
CLINICAL RHEUMATOLOGY (2009)
A proposed revision to the ACR20:: The hybrid measure of American College of Rheumatology response
David Felson et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Share Paper
